<DOC>
	<DOCNO>NCT02997163</DOCNO>
	<brief_summary>This trial investigate pharmacokinetics ( PK ) safety talazoparib patient advance solid tumor impair renal function .</brief_summary>
	<brief_title>An Open-Label Pharmacokinetics Safety Study Talazoparib</brief_title>
	<detailed_description>At End Study , patient clinically significant toxicity , contraindication continue treatment talazoparib , disease progression ( underlying cancer progression ) may eligible continue talazoparib treatment separate open-label extension study discussion Principal Investigator obtain Sponsor permission . Sponsor decision allow patient continue dose talazoparib open-label extension study base potential overall benefit-risk , patient acceptance relevant criterion .</detailed_description>
	<mesh_term>Talazoparib</mesh_term>
	<criteria>1 . Signed date informed consent form ( patient legally acceptable representative per local regulation ) obtain prior initiation studyspecific procedure treatment . 2 . Female male least 18 year age . 3 . Histologically cytologically confirm advanced solid tumor available standard approve treatment option opinion Investigator 4 . Eastern Cooperative Oncology Group ( ECOG ) Performance status ( PS ) ≤ 2 . 5 . Expected life expectancy ≥ 3 month . 6 . Able swallow study drug ( contra indication oral agent ) . 7 . Renal function screen enrollment define Modification Diet Renal Disease ( MDRD ) equation . 8 . Patient clinically significant change renal status within 3 month prior screen , accord Investigator 's review clinical patient record . 9 . Patient currently hemodialysis and/or peritoneal dialysis management chronic kidney disease acute failure/conditions . 10 . Patient unstable renal function , define change estimate glomerular filtration rate ( eGFR ) ( calculate MDRD equation ) &gt; 25 % patient mild moderate renal impaired change eGFR &gt; 30 % patient severe renal impaired , screen enrollment . 11 . Adequate organ function screen enrollment . 12 . Female patient childbearing potential must negative serum pregnancy test screening , must agree use highly effective birth control method time first dose study drug 45 day last dose study drug . 13 . Male patient must agree use condom sex pregnant woman nonpregnant female partner childbearing potential , 21 day first dose study drug 105 day last dose study drug . 14 . Female patient must breastfeed screen study participation 45 day last dose study drug . 15 . Willingness ability comply schedule visit , treatment plan , laboratory test , trial procedure . 1 . Treatment within 14 day five half life prior enrollment type systemic anticancertherapy investigational drug , whichever longer . 2 . Have recover ( recovery define CTCAE grade ≤ 1 ) acute toxicity previous anticancer standard investigational therapy , except treatmentrelated alopecia laboratory abnormality otherwise meet eligibility requirement . 3 . Major surgery within 28 day prior enrollment . 4 . Serious accompany cardiac disorder . 5 . Active know suspected brain metastasis active leptomeningeal disease undergo require treatment . 6 . Symptomatic impend spinal cord compression cauda equina syndrome . 7 . Has undergone liver transplant , kidney transplant nephrectomy . 8 . Prior allergic reaction severe intolerance ( meet criterion serious adverse event , grade 3 4 AE , permanent treatment discontinuation ) poly ADP ribose polymerase ( PARP ) inhibitor . 9 . Known myelodysplastic syndrome . 10 . Seropositive human immunodeficiency virus ( HIV ) . 11 . Any serious unstable medical condition interferes ability tolerate treatment assessment associate protocol . 12 . Gastrointestinal disorder affect absorption . 13 . Known suspected hypersensitivity talazoparib capsule component . 14 . Any condition reason interfere ability participate study , tolerate treatment assessment associate protocol , cause undue risk , complicate interpretation safety data , opinion Investigator Medical Monitor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>